Specifically, we have identified that ELAVL1 enhances HMGB3 mRNA stability and regulates the Wnt/β-catenin signaling pathway, thereby promoting glycolysis in cancer cells (Fig. 8). The gene discussed is ELAVL1; the disease is cancer.